

## Pharmakogenetik in der Praxis: warum, wie, wann? Teil 1

## Pharmacogénétique dans la pratique: pourquoi, comment, quand? Partie 1

### Literatur / Références

1. Handschin C, Meyer UA. Warum reagiert mein Patient anders auf dieses Medikament? Pharmakogenomik und personalisierte Medizin in der Praxis. Schweiz Med Forum 2012,12:425–33.
2. Table of Pharmacogenomic Biomarkers in Drug Labels. (<http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm>), 2012. Accessed 28 August 2012.
3. Arzneimittel Kompendium der Schweiz. Documed AG 2011.
4. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B\*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008,358:568–79.
5. Young B, Squires K, Patel P, Dejesus E, Bellos N, Berger D, et al. First large, multicenter, open-label study utilizing HLA-B\*5701 screening for abacavir hypersensitivity in North America. AIDS 2008,22:1673–5.
6. McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperaviciute D, Carrington M, et al. HLA-A\*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011,364:1134–43.
7. Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011,89:708–17.
8. Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 2009,15:15–21.
9. Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998,76:27–33.
10. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004,351:2827–31.
11. Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmüller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008,28:78–83.
12. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006,368:704.
13. Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoefft A, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003,105:231–8.
14. Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry 2006,30:1356–8.
15. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 2010,160:907–18.
16. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl) 1996,123:315–9.
17. Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 2004,19:17–23.
18. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004,76:536–44.